Endpoints News 生物医药· Ayisha Sharma·· 2 天前精选AI 评分65
FDA 加速批准 GSK 肺癌口服药 Nelkarmi(neladalkib)
GSK’s Nuvalent buyout delivers again as FDA clears Nelkarmi for lung cancer
AI 导读
FDA 给予 GSK 口服肺癌药物 neladalkib(商品名 Nelkarmi)加速审批。该药系 GSK 收购 Nuvalent 后获得的核心资产之一,原文明确指出此次批准发生在美国市场。
推荐理由
原文明确给出 FDA 加速审批结果,读者可据此判断该药对肺癌治疗的可用性变化及 GSK 布局进展。
正文
GSK has secured a US accelerated approval for its oral lung cancer drug neladalkib, one of two assets at the heart of its
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news